<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607436</url>
  </required_header>
  <id_info>
    <org_study_id>B-1111/139-007</org_study_id>
    <nct_id>NCT02607436</nct_id>
  </id_info>
  <brief_title>Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease</brief_title>
  <acronym>SAGE-CAD</acronym>
  <official_title>Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Progression of Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective interventional study to assess the effect of sarpogrelate compared with
      aspirin in Korean type 2 diabetic patients with atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes has been increased exponentially, arousing serious economic, social and
      health repercussions. Also, macrovascular complications of diabetes such as myocardial
      infarct or stroke have been increased. Individuals with diabetes have a greater risk of
      cardiovascular disease (CVD), approximately two to four times than that of those without
      diabetes. Currently, the U.S. Food and Drug Administration requires demonstration that new
      anti-hyperglycemic agents do not increase cardiovascular risk. The comprehensive and
      multifactorial management in type 2 diabetes, which includes control of hypertension,
      dyslipidemia and obesity, is known to significantly reduce the risk of CVD as shown in
      Steno-2 study. However, most anti-diabetic agents currently used in clinical practice do not
      seem to provide enough cardiovascular protection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary artery disease assessed by cardiac computed tomography angiography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary artery calcium score assessed by cardiac computed tomography angiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery stenosis assessed by cardiac computed tomography angiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plaque size assessed by cardiac computed tomography angiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plaque composition assessed by cardiac computed tomography angiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Ankle-branchial index</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of pulse wave velocity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism assessed by glycated hemoglobin</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism assessed by triglyceride and high density lipoprotein-cholesterol</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Sarpogrelate + Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarpogrelate as an active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin as an active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarpogrelate</intervention_name>
    <description>Sarpogrelate</description>
    <arm_group_label>Sarpogrelate + Aspirin</arm_group_label>
    <other_name>Anplag</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin</description>
    <arm_group_label>Sarpogrelate + Aspirin</arm_group_label>
    <arm_group_label>Aspirin alone</arm_group_label>
    <other_name>Aspirin protect or Astrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes with HbA1c â‰¥ 6.5% at screening visit

          -  Male or female between 30 and 80 years of age

          -  Coronary artery stenosis: 10-75% without no evidence of acute coronary syndrome

          -  No history of previous myocardial infarction

        Exclusion Criteria:

          -  Systolic blood pressure / diastolic blood pressure &gt; 160/110 mmHg

          -  Congestive heart failure

          -  Allergy to radiocontrast dye

          -  Allergy to aspirin or sarpogrelate

          -  Acute bleeding

          -  History of ulcer bleeding

          -  GOT/GPT &gt; 100/100

          -  Other antiplatelet medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNUBH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Sarpogrelate</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

